Atezolizumab is used in urothelial carcinoma for patients who cannot have cisplatin-containing chemotherapy and have PD-L1 expression on tumours, in non-small-cell lung cancer as adjuvant therapy after surgery and platinum-based chemotherapy, first-line treatment of metastatic non-small cell lung cancer with high PD-L1 expression, either alone or with bevacizumab, paclitaxel, and carboplatin. This evidence concerns the gene CD274 and non-small cell lung carcinoma.